ClinicalTrials.gg
CompletedNCT05830539Updated May 2, 2025

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

A Phase 1/2 interventional study of IN10018+PLD and IN10018+PLD+Toripalimab in Locally Advanced or Metastatic Solid Tumors, sponsored by InxMed (Shanghai) Co., Ltd.. Completed at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD and anti-PD-1 in subjects with locally advanced or metastatic solid tumors who have failed or not tolerated to at least first-line system therapy.

Read the detailed description

This study is a phase Ib/II, multicenter, open-label clinical study. This study consists of 2 parts: 1) Efficacy exploration part: including phase-Ib study (dose confirmation part) and phase II study, the purpose of phase Ib-dose confirmation part is to determine the Phase II recommended dose (RP2D) of IN10018 in combination with Pegylated liposomal doxorubicin (PLD) and programmed death-1 (PD-1) monoclonal antibody. The Phase II study will explore the antitumor efficacy and safety of IN10018 in combination with PLD or IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in subjects with locally advanced or metastatic solid tumors who have failed or are intolerant to at least first-line system therapy; 2) Efficacy confirmation part: The antitumor efficacy and safety of combination therapy in the corresponding solid tumors will be further confirmed.

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

InxMed (Shanghai) Co., Ltd. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, and aged 18 - 75 years at the time of signing the .
  2. Has ability to understand and willingness to sign informed consent(s).
  3. confirmed locally advanced or solid tumors:

    1. Cohort 1: Histologically-confirmed Locally advanced or metastatic triple-negative breast cancer.
    2. Cohort 2: Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma.
    3. Cohort 3 and 4: Histologically confirmed epithelia ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma (HGSC) only.
    4. Cohort 5: Histologically confirmed extensive-stage small cell lung cancer (according to the Veteran's Administration Lung Cancer Study Group (VALG) classification system).
    5. Cohort 6: other Histologically confirmed locally advanced or metastatic solid tumors except cohort 1-5.
  4. Have received at least 1 line of standard therapy for locally advanced or metastatic solid tumors and have failed or are not tolerable.
  5. At least one can be accurately measured per 1.1 as assessed by investigator.
  6. performance status of 0 or 1.
  7. of at least 3 months as assessed by investigator.
  8. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to first dose of study treatment.
  9. Must have recovered from all AEs due to previous therapies to ≤ Grade 1 ( 5.0) or stable status as assessed by investigator.

Exclusion criteria

Exclusion criteria

  1. Has had major surgery or significant traumatic injury within 28 days prior to first dose of study treatment, or diagnostic within 14 days prior to first dose of study treatment.
  2. Has received prior systemic anticancer therapy such as chemotherapy, biological therapy, endocrine therapy, immunotherapy, etc. within 4 weeks before the first dose.
  3. History of disease requiring systemic therapy within the past 2 years, including but not limited to autoimmune thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease.
  4. Has interstitial pneumonia currently.
  5. Has received prior treatment of any FAK inhibitor.
  6. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  7. Has a prior history of other than the study disease.
  8. Clinically symptomatic pleural effusion, pericardial effusion, or ascites, or those who have received or necessary for drainages within 3 months prior to the first dose of study treatment.
  9. Has malabsorption syndrome or inability to take oral medication.
  10. Has clinical or radiologic evidence of bowel obstruction, or prior recurrent bowel obstruction with the cause not eliminated within 3 months prior to the first dose of study treatment.
  11. Has any active infection requiring systemic therapy within 14 days prior to the first dose of study treatment.
  12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  13. Known allergy or to IN10018, PLD, or Toripalimab or their ingredients.
  14. Pregnant or lactating women.
  15. Has received prior cumulative doxorubicin or equivalent anthracyclines doses of 360 mg/m2 or more.
  16. Has received systemic treatment of , CYP2D6 or P-gp strong inhibitors/inducers within 14 days prior to the first dose of study treatment, or anticipation of the systemic treatment of these drugs during Treatment Phase.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Triple Negative Breast Cancer(TNBC)

    Group 1: IN10018 in combination with PLD in Subjects with previously-treated locally advanced or metastatic TNBC. Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated locally advanced or metastatic TNBC.

    Drug: IN10018+PLD · Drug: IN10018+PLD+Toripalimab

  • Experimental
    Head and Neck Squamous Cell Cancer(R/M-HNSCC)

    Group 1: IN10018 in combination with PLD in Subjects with previously-treated R/M-HNSCC. Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated R/M-HNSCC.

    Drug: IN10018+PLD · Drug: IN10018+PLD+Toripalimab

  • Experimental
    Platinum-resistant Ovarian Cancer

    Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with platinum-resistant ovarian cancer.

    Drug: IN10018+PLD+Toripalimab

  • Experimental
    Platinum-sensitive Ovarian Cancer(PSOC)

    Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with Platinum-sensitive recurrent ovarian cancer.

    Drug: IN10018+PLD+Toripalimab

  • Experimental
    Small Cell Lung Cancer(SCLC)

    Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated locally advanced or metastatic SCLC.

    Drug: IN10018+PLD+Toripalimab

  • Experimental
    Other solid tumor

    Group 1: IN10018 in combination with PLD in Subjects with other previously-treated locally advanced or metastatic solid tumors. Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with other previously-treated locally advanced or metastatic solid tumors.

    Drug: IN10018+PLD · Drug: IN10018+PLD+Toripalimab

Interventions

  • DrugIN10018+PLD

    IN10018 orally once daily; PLD 40mg/m2, Q4W

    Also known as: IN10018 and Doxorubicin Hydrochloride Liposome Injection

  • DrugIN10018+PLD+Toripalimab

    IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

    Also known as: IN10018 and Doxorubicin Hydrochloride Liposome Injection and Toripalimab

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D) of IN10018 in combination with PLD and anti-PD-1 monoclonal antibody.

    Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of IN10018 in combination with PLD and Toripalimab.

    Time frame: Up to 6 Months

  2. Objective response rate (ORR) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.

    Defined as the proportion of subjects with complete response (CR) or partial response (PR).

    Time frame: Up to 24 Months

Secondary outcomes

  1. Number of patients with adverse event; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG.

    Number of patients with adverse event; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG.

    Time frame: Up to 24 Months

  2. Duration of objective response (DOR) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.

    Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: Up to 24 Months

  3. Disease Control Rate (DCR) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.

    Defined as the proportion of patients with CR, PR, or stable disease (SD).

    Time frame: Up to 24 Months

  4. Progression-free survival (PFS) per RECIST v1.1 in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.

    Defined as the time from start of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: Up to 24 Months

  5. Overall survival (OS) in IN10018 combined with PLD group or in IN10018 combined with PLD and anti-PD-1 monoclonal antibody group.

    Defined as the time from the start of study treatment to the date of death due to any cause.

    Time frame: Up to 36 Months

07

Study locations

7 sites
  • Anyang Tumor Hospital
    Anyang, Henan, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi, China
  • Obstetrics & Gynecology Hospital of Fudan University
    Shanghai, Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Aug 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
Apr 26, 2023
StartActual
Mar 10, 2022
Primary completionActual
Aug 31, 2024
CompletionActual
Nov 22, 2024
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05830539
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
Mar 10, 2022
Primary completion
Aug 31, 2024
Completion
Nov 22, 2024
Last update
May 2, 2025

Study contacts

Lingying WU
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Xichun Hu
principal investigator · Fudan University
Dongmei Ji
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion